KLK3 and posterior cortical atrophy: Differences across ERSPC sites can be explained by variability in the periodicity of screening tests, rate of response to biopsy requests, level of contamination by PSA testing in the control group, or the treatments administered when a diagnosis of PCa was confirmed.